Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Madrigal Pharmaceuticals, Inc. (MDGL)

NMS · Biotechnology

$538.80-12.45 (-2.26%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$12.42B
P/E (TTM)
EPS
$-13.18
Div Yield
52W Range
$286.44–$615.00
Beta
-1.06

Company overview

Next earnings: 2026-07-30(2d)

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Peers in Biotechnology

All in industry →

Recent press releases

Madrigal Pharmaceuticals, Inc. has not issued a press release in this window.

SEC filings

All filings →

Madrigal Pharmaceuticals, Inc. has not filed an SEC document in this window.

Madrigal Pharmaceuticals, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
2,141,701 sh0.0%
1,993,687 sh0.0%
1,644,750 sh+5.5%
1,808,894 sh-0.2%
1,807,500 sh-1.4%
416,025 sh+70.3%
1,707,522 sh-10.5%
196,393 sh+180.7%

People at Madrigal Pharmaceuticals, Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
$137.3M
NI -$73.2M
06/25
$212.8M
NI -$42.3M
09/25
$287.3M
NI -$114.2M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-5.08
Prior: $-1.90
Revenue sparkline